What IGF-1 DES is
IGF-1 DES is a truncated IGF analog discussed for potent local IGF-receptor signaling in muscle and repair conversations.
IGF-1 DES is grouped under Fitness + Recovery on PeptideFactCheck because it is usually framed as a stronger or more direct anabolic peptide than broader GH-axis compounds.
The useful starting point is to separate the molecule itself from the internet story around it. It is usually framed as a stronger or more direct anabolic peptide than broader GH-axis compounds.
Why people keep looking it up
It is usually framed as a stronger or more direct anabolic peptide than broader GH-axis compounds.
IGF-1 DES is a truncated IGF analog discussed for potent local IGF-receptor signaling in muscle and repair conversations.
IGF-1 DES tends to stay in the conversation because it touches a familiar public theme: igf receptor, anabolic signaling, and tissue growth. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
High-interest anabolic signaling story with little direct human outcome support.
Direct human evidence for the common muscle-building claims is not established here.
The supporting logic is mostly built from IGF pathway biology and non-clinical models.
Why this page carries the current tier: High-interest anabolic signaling story with little direct human outcome support.
The current seed trail for IGF-1 DES is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.
Safety, limits, and regulatory context
Concerns include mitogenic signaling, tissue-selectivity assumptions, and product-quality risk.
No FDA-approved IGF-1 DES product is represented in this seed set.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for IGF-1 DES. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Clinical trial snapshot
The current ClinicalTrials.gov intervention query for IGF-1 DES returns 0 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
No linked intervention records were returned by the current ClinicalTrials.gov query terms for this page.
Literature snapshot
The current PubMed query for IGF-1 DES returns 23 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.